CA2617133C - Compositions and methods for treating bacteria - Google Patents

Compositions and methods for treating bacteria Download PDF

Info

Publication number
CA2617133C
CA2617133C CA2617133A CA2617133A CA2617133C CA 2617133 C CA2617133 C CA 2617133C CA 2617133 A CA2617133 A CA 2617133A CA 2617133 A CA2617133 A CA 2617133A CA 2617133 C CA2617133 C CA 2617133C
Authority
CA
Canada
Prior art keywords
nisin
mupirocin
bacteria
composition
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2617133A
Other languages
English (en)
French (fr)
Other versions
CA2617133A1 (en
Inventor
Scott Michael Walsh
Mary Catherine Pittaway
James J. Mond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosynexus Inc
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Publication of CA2617133A1 publication Critical patent/CA2617133A1/en
Application granted granted Critical
Publication of CA2617133C publication Critical patent/CA2617133C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2617133A 2005-07-28 2006-07-28 Compositions and methods for treating bacteria Expired - Fee Related CA2617133C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70301005P 2005-07-28 2005-07-28
US60/703,010 2005-07-28
US72519305P 2005-10-11 2005-10-11
US60/725,193 2005-10-11
US77903406P 2006-03-03 2006-03-03
US60/779,034 2006-03-03
PCT/US2006/029672 WO2007014372A2 (en) 2005-07-28 2006-07-28 Compositions and methods for treating bacteria

Publications (2)

Publication Number Publication Date
CA2617133A1 CA2617133A1 (en) 2007-02-01
CA2617133C true CA2617133C (en) 2014-09-30

Family

ID=37684026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2617133A Expired - Fee Related CA2617133C (en) 2005-07-28 2006-07-28 Compositions and methods for treating bacteria

Country Status (6)

Country Link
US (2) US7517852B2 (enExample)
EP (1) EP1940437B1 (enExample)
JP (1) JP5619352B2 (enExample)
CA (1) CA2617133C (enExample)
ES (1) ES2436614T3 (enExample)
WO (1) WO2007014372A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940437B1 (en) * 2005-07-28 2013-09-04 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
US9115358B2 (en) 2006-08-11 2015-08-25 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College MOENOMYCIN ANALOGUE, SYNTHESIS PROCESS AND USE
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
JP5374260B2 (ja) * 2009-07-10 2013-12-25 静岡商工会議所 農業用資材
US9220675B2 (en) 2010-09-09 2015-12-29 Mary Kay Inc. Topical skin care formulations comprising plant extracts
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
CA2865237C (en) * 2012-02-28 2017-08-15 Marrone Bio Innovations, Inc. Control of phytopathogenic microorganisms with pseudomonas sp. and substances and compositions derived therefrom
EP2850090B1 (en) 2012-04-06 2018-10-03 President and Fellows of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
US9273084B2 (en) 2012-04-06 2016-03-01 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
WO2013151697A1 (en) 2012-04-06 2013-10-10 President And Fellows Of Harvard College Methods and compounds for identifying glycosyltransferase inhibitors
EP3194609B1 (en) 2014-09-16 2019-08-28 President and Fellows of Harvard College Engineered water nanostructures (ewns) and uses thereof
US10617703B2 (en) * 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12502370B2 (en) * 2019-04-11 2025-12-23 Cmpd Licensing, Llc Wound treatments and compositions
EP3331496B1 (en) * 2015-08-05 2021-01-27 The University of Rochester Antimicrobial compositions comprising mupirocin and neomycin
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
EP3435765A1 (en) 2016-03-31 2019-02-06 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
JP2019510036A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティクス／プレバイオティクス有効成分を含む清浄剤組成物
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2019081309A1 (en) 2017-10-27 2019-05-02 OCE Holding B.V. MULTI-ROLL PRINTER CONTROL DEVICE, PRINTING SYSTEM, AND MULTI-ROLL PRINTER CONTROL METHOD
CA3128389A1 (en) * 2019-03-08 2020-09-17 Fraunhofer Usa, Inc. Novel antimicrobial lantibiotic peptide and uses thereof
US12156875B2 (en) 2019-04-11 2024-12-03 Cmpd Licensing, Llc Wound treatments and compositions
US12433853B2 (en) 2019-08-26 2025-10-07 Kent State University Rationally designed lawsone derivatives as antimicrobials against multidrug-resistant Staphylococcus aureus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260271A (en) 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
US5135910A (en) * 1988-06-22 1992-08-04 The Public Health Research Institute Of The City Of New York Nisin compositions for use as enhanced, broad range bactericides
EP0579730B1 (en) * 1991-04-11 2003-02-26 Stichting Nederlands Instituut Voor Zuivelonderzoek (Nizo) Lantibiotics similar to nisin a, lactic acid bacteria which produce such lantibiotics, method for constructing such lactic acid bacteria and method for preserving foodstuffs with the aid of these lantibiotics and these lactic acid bacteria producing lantibiotics
DE69427492T2 (de) 1993-08-20 2002-04-18 Novartis Ag, Basel Verfahren zur prävention und behandlung der rindermastitis
GB9423404D0 (en) * 1994-11-19 1995-01-11 Biotech & Biolog Scien Res Production of nisin
BR9609281A (pt) * 1995-06-23 1999-06-15 Ambi Inc Método para o controle de bactérias gram-positivas resistentes a antibióticos e tratamento de infecções
US5928146A (en) * 1996-03-15 1999-07-27 Hitachi Medical Corporation Inspection apparatus using nuclear magnetic resonance
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
IL123143A (en) * 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
ES2532906T5 (es) * 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
EP1940437B1 (en) * 2005-07-28 2013-09-04 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections

Also Published As

Publication number Publication date
JP2009502965A (ja) 2009-01-29
US20070060506A1 (en) 2007-03-15
JP5619352B2 (ja) 2014-11-05
US20090196945A1 (en) 2009-08-06
WO2007014372A3 (en) 2007-07-26
US8697639B2 (en) 2014-04-15
WO2007014372A2 (en) 2007-02-01
CA2617133A1 (en) 2007-02-01
ES2436614T3 (es) 2014-01-03
EP1940437A4 (en) 2009-08-19
US7517852B2 (en) 2009-04-14
EP1940437A2 (en) 2008-07-09
EP1940437B1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
US8697639B2 (en) Compositions and methods for treating bacteria
US20090304783A1 (en) Compositions and methods for treating bacteria
BR122019015601B1 (pt) produto, substrato, composição farmacêutica e uso de um produto
Weber et al. Antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery
O'Reilly et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin
US20210260101A1 (en) Potentiated antibiotic compositions and methods of use for treating bacterial infections and biofilms
AU2011231112B2 (en) Compositions for topical administration
EP1044006A1 (en) Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
WO2007092582A2 (en) Neutralization of bacterial spores
US20230293628A1 (en) Means and methods for treating bacterial infections
Khan et al. Comparative evaluation of effectiveness of nisin, amoxicillin/clavulanic acid (Augmentin) and chlorhexidine on E. faecalis as an intracanal irrigant: an in-vitro study
US20210205352A1 (en) Antibiotic compositions and methods of use
Shankar et al. Newer antibiotics
Gardam et al. Disinfectants and Antiseptics
WO2022180380A1 (en) Combination of mupirocin with porphyrin-based photosensitizers for reducing antibiotic resistance emergence
RU1790409C (ru) Способ лечени гнойно-воспалительного процесса
Moise et al. Staphylococcus aureus: resistance update and treatment options
EP4157306A1 (en) Modified plyss2 lysins and antibiotic combinations for use against gram-positive bacteria
NZ523982A (en) Combinations of dalfopristine / quinupristine with cefpirome useful in bactericidal or bacteriostatic treatment
Gawande et al. Antibiofilm and Antimicrobial Efficacy of DispersinB (registered trademark)-KSL-W Peptide-Based Wound Gel Against Chronic Wound Infection Associated Bacteria
AU2014200086A1 (en) Compositions for topical administration

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170728